RGTI - Rigetti Computing Inc.

One of the first three to convert its letter of intent into a signed definitive agreement, receiving $100M in three installments. Touts fully in-house design, manufacturing (Fremont, CA) and software, plus a tiled multi-chip architecture (108-qubit Cephus). Presented as a core opportunity in the government-backed quantum buildout.

Host explains Rigetti's gate-based superconducting quantum approach, its 108-qubit system available via cloud, and partnership with HPE and Pittsburgh Supercomputing Center. He notes it's an early-stage company with tiny revenue ($5.1M) and heavy losses but a strong cash position ($551M, no debt). He doesn't call it a buy, emphasizing it requires a 3-8 year mindset and that investors are buying future commercial potential, not current profits.

Rigetti is very volatile but bouncing off major support around $13-$14.50. The big-money trade analyzed is buying June 2027 $15 calls. Hosts cite an excellent risk/reward ratio, targeting solid resistance around $23.30 with a stop under the recent low.

Rigetti has positive margin trends and its own fab, but he remains cautious and won't buy until the stock breaks $20.

Quantum computing company with superconducting systems. Average price target $30.71 implies 71% upside; most bullish target of $40 implies 123% upside. However, the technology is speculative with development delays and insider selling noted as risks. The long-term potential of quantum-AI convergence is the main bullish thesis.

Selling off; if breaks through $13.95, continued downside.

Broke below $15 support, continuation likely if it breaks under $14.90, targeting $12.50.

One of the leading pure-play quantum companies, offers cloud-based quantum computing, secured government funding and partnerships.

Vertically integrated superconducting qubit maker with own fab (Fab 1); volatile but could reward patient investors if superconducting QC progresses over the next decade.

Full-stack superconducting quantum company with own manufacturing facility (Fab 1); could reward patient investors.